Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma
Tratamiento con hemodiálisis del fracaso renal agudo en el mieloma múltiple con filtros de alto poro (high cut-off)
Guillermo Martín-Reyesa, Remedios Toledo-Rojasa, Álvaro Torres-de Ruedaa, Eugenia Sola-Moyanoa, Lourdes Blanca-Martosa, Laura Fuentes-Sáncheza, M. Dolores Martínez-Estebana, M. José Díez-de los Ríosb, Alicia Bailén-Garcíac, Miguel González-Molinaa, Isabel García-Gonzálezd
a Servicio de Nefrología, Hospital Regional Universitario Carlos Haya, Málaga,
b Laboratorio de Análisis Clínicos, Hospital Regional Universitario Carlos Haya, Málaga,
c Servicio de Hematología, Hospital Regional Universitario Carlos Haya, Málaga,
d Servicio de Anatomía Patológica, Hospital Regional Universitario Carlos Haya, Málaga,
Read
15260
Timeswas read the article
2977
Total PDF
12283
Total HTML
Share statistics
array:21 [ "pii" => "X2013251412000570" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Nov.11094" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:35-43" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7726 "formatos" => array:3 [ "EPUB" => 337 "HTML" => 6574 "PDF" => 815 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699512000573" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2011.Nov.11094" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2012;32:35-43" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 14450 "formatos" => array:3 [ "EPUB" => 292 "HTML" => 13297 "PDF" => 861 ] ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Tratamiento con hemodiálisis del fracaso renal agudo en el mieloma múltiple con filtros de alto poro (high cut-off)" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "35" "paginaFinal" => "43" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11094_108_22750_es_11094_t1.jpg" "Alto" => 192 "Ancho" => 600 "Tamanyo" => 112413 ] ] "descripcion" => array:1 [ "es" => "Características de los seis pacientes diagnosticados de mieloma múltiple" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Guillermo Martín-Reyes, Remedios Toledo-Rojas, Álvaro Torres-de Rueda, Eugenia Sola-Moyano, Lourdes Blanca-Martos, Laura Fuentes-Sánchez, M. Dolores Martínez-Esteban, M. José Díez-de los Ríos, Alicia Bailén-García, Miguel González-Molina, Isabel García-González" "autores" => array:11 [ 0 => array:2 [ "nombre" => "Guillermo" "apellidos" => "Martín-Reyes" ] 1 => array:2 [ "nombre" => "Remedios" "apellidos" => "Toledo-Rojas" ] 2 => array:2 [ "nombre" => "Álvaro" "apellidos" => "Torres-de Rueda" ] 3 => array:2 [ "nombre" => "Eugenia" "apellidos" => "Sola-Moyano" ] 4 => array:2 [ "nombre" => "Lourdes" "apellidos" => "Blanca-Martos" ] 5 => array:2 [ "nombre" => "Laura" "apellidos" => "Fuentes-Sánchez" ] 6 => array:2 [ "nombre" => "M. Dolores" "apellidos" => "Martínez-Esteban" ] 7 => array:2 [ "nombre" => "M. José" "apellidos" => "Díez-de los Ríos" ] 8 => array:2 [ "nombre" => "Alicia" "apellidos" => "Bailén-García" ] 9 => array:2 [ "nombre" => "Miguel" "apellidos" => "González-Molina" ] 10 => array:2 [ "nombre" => "Isabel" "apellidos" => "García-González" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251412000570" "doi" => "10.3265/Nefrologia.pre2011.Nov.11094" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000570?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000573?idApp=UINPBA000064" "url" => "/02116995/0000003200000001/v0_201502091357/X0211699512000573/v0_201502091357/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251412000562" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Sep.10988" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:44-52" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7213 "formatos" => array:3 [ "EPUB" => 337 "HTML" => 5886 "PDF" => 990 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Early biomarkers of acute kidney failure after heart angiography or heart surgery in patients with acute coronary syndrome or acute heart failure." "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "44" "paginaFinal" => "52" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Biomarcadores precoces de fracaso renal agudo tras angiografía coronaria o cirugía cardíaca en pacientes con síndrome coronario o fallo cardíaco agudos" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "10988_108_23959_en_10988t1.jpg" "Alto" => 458 "Ancho" => 600 "Tamanyo" => 166694 ] ] "descripcion" => array:1 [ "en" => "Clinical and demographic characteristics of patients that underwent coronary angiography" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Isidro Torregrosa, Carmina Montoliu, Amparo Urios, Isabel Juan, Nisrin ElMlili, María Jesús Puchades, Miguel Angel Solís, Rafael Sanjuán, Maria Luisa Blasco, Carmen Ramos, Patricia Tomás, José Ribes, Arturo Carratalá, Alfonso Miguel" "autores" => array:16 [ 0 => array:2 [ "nombre" => "Isidro" "apellidos" => "Torregrosa" ] 1 => array:2 [ "nombre" => "Carmina" "apellidos" => "Montoliu" ] 2 => array:2 [ "nombre" => "Amparo" "apellidos" => "Urios" ] 3 => array:2 [ "nombre" => "Isabel" "apellidos" => "Juan" ] 4 => array:2 [ "nombre" => "Nisrin" "apellidos" => "ElMlili" ] 5 => array:2 [ "nombre" => "María Jesús" "apellidos" => "Puchades" ] 6 => array:2 [ "nombre" => "Miguel Angel" "apellidos" => "Solís" ] 7 => array:2 [ "nombre" => "Rafael" "apellidos" => "Sanjuán" ] 8 => array:2 [ "nombre" => "Maria Luisa" "apellidos" => "Blasco" ] 9 => array:2 [ "nombre" => "Carmen" "apellidos" => "Ramos" ] 10 => array:2 [ "nombre" => "Patricia" "apellidos" => "Tomás" ] 11 => array:2 [ "nombre" => "José" "apellidos" => "Ribes" ] 12 => array:2 [ "nombre" => "Arturo" "apellidos" => "Carratalá" ] 13 => array:2 [ "nombre" => "Nisrin" "apellidos" => "ElMlili" ] 14 => array:2 [ "nombre" => "Isabel" "apellidos" => "Juan" ] 15 => array:2 [ "nombre" => "Alfonso" "apellidos" => "Miguel" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512000565" "doi" => "10.3265/Nefrologia.pre2011.Sep.10988" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000565?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000562?idApp=UINPBA000064" "url" => "/20132514/0000003200000001/v0_201502091620/X2013251412000562/v0_201502091620/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251412000597" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Oct.11121" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:28-34" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 8223 "formatos" => array:3 [ "EPUB" => 332 "HTML" => 7169 "PDF" => 722 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Start-up of a clinical sample processing, storage and management platform: organisation and development of the REDinREN Biobank" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "28" "paginaFinal" => "34" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Puesta en marcha de una plataforma de proceso, almacenamiento y gestión de muestras clínicas: organización y desarrollo del Biobanco de REDinREN" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11121_16025_25922_en_t111121.jpg" "Alto" => 567 "Ancho" => 1094 "Tamanyo" => 803375 ] ] "descripcion" => array:1 [ "en" => "Biobank objectives" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "LAURA CALLEROS, Laura Calleros*, MARIA A CORTES, María A. Cortés*, ALICIA LUENGO, Alicia Luengo, INES MORA, Inés Mora, BRENDA GUIJARRO, Brenda Guijarro, PALOMA MARTIN, Paloma Martín, ALBERTO Ortiz Arduán, Alberto Ortiz-Arduán, RAFAEL Selgas, Rafael Selgas, DIEGO RODRIGUEZ-PUYOL, Diego Rodríguez-Puyol, MANUEL RODRIGUEZ-PUYOL, Manuel Rodríguez-Puyol" "autores" => array:20 [ 0 => array:2 [ "nombre" => "LAURA" "apellidos" => "CALLEROS" ] 1 => array:2 [ "nombre" => "Laura" "apellidos" => "Calleros*" ] 2 => array:2 [ "nombre" => "MARIA A" "apellidos" => "CORTES" ] 3 => array:2 [ "nombre" => "María A." "apellidos" => "Cortés*" ] 4 => array:2 [ "nombre" => "ALICIA" "apellidos" => "LUENGO" ] 5 => array:2 [ "nombre" => "Alicia" "apellidos" => "Luengo" ] 6 => array:2 [ "nombre" => "INES" "apellidos" => "MORA" ] 7 => array:2 [ "nombre" => "Inés" "apellidos" => "Mora" ] 8 => array:2 [ "nombre" => "BRENDA" "apellidos" => "GUIJARRO" ] 9 => array:2 [ "nombre" => "Brenda" "apellidos" => "Guijarro" ] 10 => array:2 [ "nombre" => "PALOMA" "apellidos" => "MARTIN" ] 11 => array:2 [ "nombre" => "Paloma" "apellidos" => "Martín" ] 12 => array:2 [ "nombre" => "ALBERTO" "apellidos" => "Ortiz Arduán" ] 13 => array:2 [ "nombre" => "Alberto" "apellidos" => "Ortiz-Arduán" ] 14 => array:2 [ "nombre" => "RAFAEL" "apellidos" => "Selgas" ] 15 => array:2 [ "nombre" => "Rafael" "apellidos" => "Selgas" ] 16 => array:2 [ "nombre" => "DIEGO" "apellidos" => "RODRIGUEZ-PUYOL" ] 17 => array:2 [ "nombre" => "Diego" "apellidos" => "Rodríguez-Puyol" ] 18 => array:2 [ "nombre" => "MANUEL" "apellidos" => "RODRIGUEZ-PUYOL" ] 19 => array:2 [ "nombre" => "Manuel" "apellidos" => "Rodríguez-Puyol" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X021169951200059X" "doi" => "10.3265/Nefrologia.pre2011.Oct.11121" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X021169951200059X?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000597?idApp=UINPBA000064" "url" => "/20132514/0000003200000001/v0_201502091620/X2013251412000597/v0_201502091620/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "titulo" => "Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "35" "paginaFinal" => "43" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Guillermo Martín-Reyes, Remedios Toledo-Rojas, Álvaro Torres-de Rueda, Eugenia Sola-Moyano, Lourdes Blanca-Martos, Laura Fuentes-Sánchez, M. Dolores Martínez-Esteban, M. José Díez-de los Ríos, Alicia Bailén-García, Miguel González-Molina, Isabel García-González" "autores" => array:11 [ 0 => array:4 [ "nombre" => "Guillermo" "apellidos" => "Martín-Reyes" "email" => array:1 [ 0 => "gmartínr@senefro.org" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "nombre" => "Remedios" "apellidos" => "Toledo-Rojas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 2 => array:3 [ "nombre" => "Álvaro" "apellidos" => "Torres-de Rueda" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 3 => array:3 [ "nombre" => "Eugenia" "apellidos" => "Sola-Moyano" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 4 => array:3 [ "nombre" => "Lourdes" "apellidos" => "Blanca-Martos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 5 => array:3 [ "nombre" => "Laura" "apellidos" => "Fuentes-Sánchez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 6 => array:3 [ "nombre" => "M. Dolores" "apellidos" => "Martínez-Esteban" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 7 => array:3 [ "nombre" => "M. José" "apellidos" => "Díez-de los Ríos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 8 => array:3 [ "nombre" => "Alicia" "apellidos" => "Bailén-García" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] ] ] 9 => array:3 [ "nombre" => "Miguel" "apellidos" => "González-Molina" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 10 => array:3 [ "nombre" => "Isabel" "apellidos" => "García-González" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital Regional Universitario Carlos Haya, Málaga, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Laboratorio de Análisis Clínicos, Hospital Regional Universitario Carlos Haya, Málaga, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] 2 => array:3 [ "entidad" => "Servicio de Hematología, Hospital Regional Universitario Carlos Haya, Málaga, " "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] 3 => array:3 [ "entidad" => "Servicio de Anatomía Patológica, Hospital Regional Universitario Carlos Haya, Málaga, " "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento con hemodiálisis del fracaso renal agudo en el mieloma múltiple con filtros de alto poro (high cut-off)" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11094_16025_26255_en_t111094.jpg" "Alto" => 678 "Ancho" => 2178 "Tamanyo" => 470403 ] ] "descripcion" => array:1 [ "en" => "Characteristics of the six patients diagnosed with multiple myeloma" ] ] ] "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Multiple myeloma (MM) is a plasma cell neoplasm that causes acute renal failure (ARF) in 12%-20% of cases, whether as an initial manifestation of the myeloma or during the course of evolution of the disease following diagnosis.<span class="elsevierStyleSup">1 </span>The survival of these patients will depend on whether or not they recover renal function, not only due to the complications derived from the renal failure itself, but also from the reduced possibility of access to more effective treatments.<span class="elsevierStyleSup">2,3</span> Renal function is not recovered in 75% of dialysis-dependent patients,<span class="elsevierStyleSup">4-7</span> and their mean survival on renal replacement therapy is less than 1 year.<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara">Cast nephropathy is the most common cause of ARF and plays a role in over 55% of cases, and 75% of those that require dialysis.<span class="elsevierStyleSup">9,10</span> The formation of casts in the distal tubules, caused by the deposition of light chains and Tamm-Horsfall protein, is the main cause of renal failure in these patients<span class="elsevierStyleSup">11-14</span>; as such, it is essential to rapidly reduce blood levels of free light chains in order to facilitate the recovery of renal function.<span class="elsevierStyleSup">15</span></p><p class="elsevierStylePara">Chemotherapy treatments for MM have improved greatly in the last decade, and regimens involving bortezomib, melphalan, thalidomide, and lenalidomide have improved the prognosis of these patients.<span class="elsevierStyleSup">16</span> One coadjuvant therapy for this disease has been reducing free light chain levels using extracorporeal purifying techniques. Plasmapheresis has been used for many years to reduce the circulating levels of light chains, although the efficacy of this treatment in recovering renal function has not been clearly demonstrated.<span class="elsevierStyleSup">17</span> This has caused researchers to search for new techniques that can effectively remove light chains and improve the recovery rate of renal function. To this end, Hutchison et al, using high cut-off (HCO) dialysers and long haemodialysis sessions (8 hours), have achieved good results in these patients, with recovery rates over 60%.<span class="elsevierStyleSup">18</span></p><p class="elsevierStylePara">We present the evolution of six patients with myeloma and acute renal failure that were treated with these HCO filters, as well as the complications that arise with this type of haemodialysis, and review the pros and cons of this technique.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">MATERIAL AND METHOD</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Six patients diagnosed with MM and ARF requiring dialysis and with serum light chain levels >500mg/l were treated with haemodialysis using HCO 1100<span class="elsevierStyleSup">®</span> (1m<span class="elsevierStyleSup">2</span>) or Theralite<span class="elsevierStyleSup">®</span> (2.1m<span class="elsevierStyleSup">2</span>) high cut-off filters made from polyaryl ether sulfone/polyvinyl pyrrolidone (Gambro Dyalisatorem, Henchingen, Germany).<span class="elsevierStyleSup">19</span> These filters are designed to increase the permeability of substances smaller than 60kD. The only difference between them is the greater surface area of the membrane, which increases the efficacy in removing light chains and produces a greater loss of albumin. We used Theralite<span class="elsevierStyleSup">®</span> (2.1m<span class="elsevierStyleSup">2</span>) filters when they were commercially available. The haemodialysis sessions involved standard haemodialysis monitors, lasted for 8 hours, involved a blood flow of 200ml/min-250ml/min, and had an ultrapure dialysate flow rate of 500ml/min. Sodium heparin was applied at 3000IU to start with, and 500IU at each hour. At the end of each session, 20% albumin was administered (100cc) along with monosodium phosphate (10ml) and magnesium sulphate (10ml), following the protocol set out by Hutchison et al.<span class="elsevierStyleSup">20</span> The goal was to perform 5 sessions on consecutive days, followed by sessions on alternating days until renal function was recovered or until light chain levels fell below 500mg/l. Ultrafiltration was programmed according to the clinical needs of each patient.</p><p class="elsevierStylePara">Before and after each session, mean free light chain levels were measured in terms of mg/l using nephelometry (FREELITE<span class="elsevierStyleSup">®</span>; The Binding Site, Birmingham, UK),<span class="elsevierStyleSup">21</span> and creatinine, albumin, phosphorous, calcium, and magnesium were measured before each session. These measurements were also taken after each session in the first patient. In cases requiring a renal biopsy, an analysis was performed using a light microscope and immunofluorescence with standard techniques, including the detection of anti-kappa and lambda light chain antibodies by immunofluorescence. We also used a Congo red stain test.</p><p class="elsevierStylePara">At the same time, patients were treated with chemotherapy regimens according to the protocols of the haematology department.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Three men and three women were admitted to the nephrology department for ARF of an unknown cause and were finally diagnosed with MM. The characteristics of the patients are summarised in Table 1. Three patients were younger than 60 years, and the other three were older than 70. The initial symptoms were bone pain in four cases, one patient sought treatment for constitutional syndrome, and the sixth patient was admitted under the diagnosis of unconfirmed pancreatitis and renal failure. The start of symptoms varied greatly, between 7 days and over a year (6<span class="elsevierStyleSup">th</span> patient). In this patient, a review of the clinical history revealed that a monoclonal gammopathy and bone infarcts had been detected one year before, requiring health care, but with an incomplete analysis. The patients that took the longest time to be diagnosed were those that did not recover renal function.</p><p class="elsevierStylePara">Three patients had kappa light chain myeloma, two had lambda IgG myeloma, and one had IgA kappa myeloma. The bone marrow was infiltrated to a varying degree by plasma cells of an anomalous phenotype that are characteristic of the disease. Four patients underwent a renal biopsy: two were diagnosed with cast nephropathy and the other two were diagnosed with cast nephropathy and light chain deposition disease. Immunofluorescence was positive in glomerular samples for light chains in two of the deposition disease cases, and in the tubules and cylinders of all four cases. Interstitial damage was mild, and tubular reactivity with marked regenerative changes was similar in all cases. None of the Congo red stain tests resulted positive. One patient refused the biopsy (case 3), and the health of another (case 4) negated that possibility. Proteinuria ranged between 6680mg/dl and 570mg/dl, with no correlation observed with serum free light chain levels or histological findings.</p><p class="elsevierStylePara">The number of days of hospitalisation, days to diagnosis, days to start of HCO-HD, as well as the number of days elapsed between hospitalisation and the start of chemotherapy are shown in Table 2. The first three patients were treated with vincristine, adriamycin, and dexamethasone, and the last three were given bortezomib and melphalan and/or prednisone, according to the protocols of the haematology department.</p><p class="elsevierStylePara">It total, the six patients underwent 90 sessions of haemodialysis, with a range of 6-40 sessions each. The HCO-HD was interrupted due to: a) renal function recovery in three cases (cases 1, 3, and 5); b) in case 2, the start of HCO-HD was delayed several days since the patient had a large inguinal haematoma following catheterisation of the femoral vein, and <span class="elsevierStyleItalic">a posteriori</span> analysis showed that light chain levels had fallen below 500mg/l; c) in case 4, treatment was interrupted upon finding that the patient’s light chain levels remained above 700mg/l and anuria continued even after 7 sessions of haemodialysis; and d) in case 6, treatment was discontinued after 40 sessions of HCO-HD and three cycles of bortezomib and prednisone in the absence of a response, with light chains remaining at 2760mg/l and persistent oliguria.</p><p class="elsevierStylePara">The percentage reduction in light chain levels from the start of treatment to the end of treatment in each patient is summarised in Figure 1, and was very high in all patients except for patient 6, who did not respond to chemotherapy treatment, with a small reduction in light chain levels (12.6%). In the other five patients, levels decreased by over 65%. In 56 sessions in which pre and post-HD light chain levels were measured, the mean percentage reduction in light chain levels was 54.98%±17.27% (Figure 2 and Figure 3). There were no differences in the reduction of lambda and kappa light chains (kappa: 53.52%±18.6% vs lambda 57.82%±14.2%), or between results when using 1.1m<span class="elsevierStyleSup">2</span> HCO or 2.2m<span class="elsevierStyleSup">2</span> Theralite<span class="elsevierStyleSup">®</span> filters (56%±19% vs 53%±15%, respectively).</p><p class="elsevierStylePara">In 25 haemodialysis sessions (28%), several complications/events were registered. These are discussed in Table 3. On 12 occasions (48%), the complications were due to system coagulations (8 episodes in patient 6), requiring a suspension of the session on three occasions. Reduced flow and catheter obstruction were the causes of 8 other episodes (32%). Other complications were irrelevant.</p><p class="elsevierStylePara">There were no major changes in predialysis albumin levels when using this method, although patients that were treated using the 2.1m<span class="elsevierStyleSup">2</span> Theralite<span class="elsevierStyleSup">®</span> filter had a greater decrease in albumin, requiring increased doses after dialysis (cases 5 and 6). Although calcium, phosphorous, and magnesium levels were slightly reduced in several cases, this change had no clinical significance (Table 4). Other complications in the evolution of our study patients were: two infections (one resulted in a positive blood culture for <span class="elsevierStyleItalic">Escherichia coli</span>, the other one testing negative) and one stroke with complete recovery.</p><p class="elsevierStylePara">In three patients, renal function was recovered (cases 1, 3, and 5), and these patients remain alive and free of dialysis. Case 1 received a bone marrow transplant and has had favourable evolution for three and a half years; case 3 has been monitored for two years 8 months, and case 5 for 8 months. Of the three cases that did not recover renal function, one patient died 4 months after starting haemodialysis; in the other two cases, the patients are still alive, although they continue to depend on dialysis (case 2: 2 years, 10 months; case 6: 4 months). In the two cases that did not recover renal function and had undergone a renal biopsy, cast nephropathy was accompanied by deposition disease, whereas in the two cases that underwent a biopsy and recovered renal function, the cast nephropathy was the sole diagnosis.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Based on our experience, patients with MM and ARF with cast nephropathy can recover renal function through combined treatment with chemotherapy and long haemodialysis sessions with HCO filters, as occurred in at least 50% of the patients in our small study.</p><p class="elsevierStylePara">Recent studies have demonstrated that a rapid decrease in free light chain levels with chemotherapy and extracorporeal techniques is associated with recovered renal function.<span class="elsevierStyleSup">15,22-24</span> Several studies have evaluated the efficacy of plasmapheresis in the treatment of myeloma-related renal failure. The study by Zucchelli et al,<span class="elsevierStyleSup">23</span> and more importantly, the study by Johnson<span class="elsevierStyleSup">24</span> demonstrated a better patient evolution in those cases that were treated with plasmapheresis vs those that were not; however, the small sample size, the fact that not all patients had cast nephropathy, and the use of different dialysis methods significantly limited the conclusions made in this study. Afterwards, Clark<span class="elsevierStyleSup">17 </span>published a randomised, controlled study involving 97 patients, the largest study available in the literature. In this study, plasmapheresis did not achieve superior results in terms of death, dependence on dialysis, and glomerular filtration rate (<30%ml/min/1.73m<span class="elsevierStyleSup">2</span>). However, Leung<span class="elsevierStyleSup">15</span> found that plasmapheresis was effective at recovering renal function (mean time: 2 months) if the renal damage was due to cast nephropathy and the level of free light chains decreased by at least 50%. In summary, the efficacy of plasmapheresis in myeloma kidney is uncertain at best, and has yet to be fully upheld as a valid treatment after the publication of only a small number of studies with few patients. The reason for this is that plasmapheresis only purifies the intravascular space (17%) and not at the quantity necessary to provide a benefit to many patients, since the reduction in light chain levels depends primarily on the level of production.<span class="elsevierStyleSup">5</span> Furthermore, plasmapheresis cannot be sustained for a very long time.</p><p class="elsevierStylePara">Since 2007, the use of long haemodialysis sessions with membranes that are permeable to proteins has been proposed in order to increase the extraction rate of light chains up to 90% during three weeks.<span class="elsevierStyleSup">20</span> In this study, HCO filters (Gambro) with a cut-off of 45kD were superior to four different high-flux dialysers (10kD) and two super-flux dialysers (20kD) in clearing light chains (22.5-31kD). In this same study, the HCO filter was tested in 11 patients with myeloma and requiring haemodialysis who underwent different chemotherapies. Of the 11 patients diagnosed with cast nephropathy based on a renal biopsy, 5 underwent dialysis on a daily basis for one week and afterwards on alternating days; 3 recovering renal function. In the 2 patients that did not recover renal function, infections forced an interruption of the chemotherapy provided, with a consequent rebound in light chain levels. Later, these same authors reported their experience with 19 patients with renal biopsies showing cast nephropathy, 13 of which recovered renal function. Of the 6 patients in which chemotherapy had to be suspended, only one recovered renal function, which appears to suggest that the extraction of light chains using this method is only useful when accompanied by a response to chemotherapy.<span class="elsevierStyleSup">18</span></p><p class="elsevierStylePara">Following the first experience by Hutchison et al, we started treating patients with MM and ARF from cast nephropathy with this method of haemodialysis, with similar results to those from previous authors. In our six patients, the extraction of light chains in each long haemodialysis session with HCO filters reduced light chain levels by 53%-57%, similar to the results reported by Hutchison. At the end of the treatment, our patients had experienced decreases of over 70% over the initial values, except for patient number 6, who, despite the fact that haemodialysis was effective in reducing light chain levels, did not respond to chemotherapy and never recovered renal function, as occurred in Hutchison’s patients.<span class="elsevierStyleSup">18</span></p><p class="elsevierStylePara">We did not observe severe complications during haemodialysis sessions in our study, and with the replacement of lost albumin, calcium, phosphates, and magnesium, we reached acceptable levels in all these parameters. The use of 2.1m<span class="elsevierStyleSup">2</span> filters did result in a greater loss of albumin, which required increased doses to replenish albumin levels after dialysis sessions, using a double filter.<span class="elsevierStyleSup">25</span> The two infectious complications produced were not significant, and did not require halting the chemotherapy regimen.</p><p class="elsevierStylePara">With regard to the recovery of renal function, our results are similar to Hutchison’s<span class="elsevierStyleSup">18</span>: approximately 60% of patients recovered renal function using this technique.<span class="elsevierStyleSup">22 </span>Several factors influenced these results: 1) the time elapsed between the start of symptoms and the diagnosis of myeloma. In our study, the three patients that did not recover renal function were those that had suffered symptoms for the longest amount of time (60 days, 120 days, and 1 year). 2) Histological findings: the 2 patients that underwent a renal biopsy and did not recover renal function had deposition disease, in addition to cast nephropathy. This situation involves a poor prognosis and short life expectancy.<span class="elsevierStyleSup">26</span> 3) The speed with which chemotherapy treatment is started and the response to this treatment. 4) The efficacy in removing light chains in haemodialysis using high cut-off filters. The possibility of recovery was 80% in patients whose light chain levels decreased by 60% after three weeks of treatment.<span class="elsevierStyleSup">18</span></p><p class="elsevierStylePara">There is still no proven evidence that this technique clearly contributes to improve survival in patients with MM and cast nephropathy, or that this type of treatment is superior to plasmapheresis, which has not demonstrated its effectiveness either. Currently, a randomised controlled study (EuLITE) is underway, involving 90 newly diagnosed patients with myeloma caused by cast nephropathy and dialysis-dependent renal failure. All patients will receive bortezomib and will be randomised to treatment with standard haemodialysis or HCO filter haemodialysis. The primary variable is independence from dialysis after three months of treatment.<span class="elsevierStyleSup">27</span> If results are favourable for this technique, it will then be compared with plasmapheresis.</p><p class="elsevierStylePara">Additionally, one limitation for the use of this technique is its high economic cost. Grima<span class="elsevierStyleSup">28</span> recently presented a cost-effectiveness model comparing the treatment of myeloma kidney with HCO filters vs standard haemodialysis. This study found that the treatment of myeloma kidney with long haemodialysis sessions using HCO filters could substantially improve renal recovery in patients with multiple myeloma, compared to the standard haemodialysis. This results in an improved life expectancy and overall savings, without the need for chronic haemodialysis. The model predicts a mean survival of 19.92 months in patients treated with standard haemodialysis vs 33.9 months using the new technique, with a total savings of 6000 pounds sterling per patient.</p><p class="elsevierStylePara">In conclusion, the poor prognosis of patients with MM and ARF due to cast nephropathy requiring dialysis, the relationship between reduced light chain levels and the recovery of renal function suggest the potential benefit of early chemotherapy combined with a method for the extra-corporeal removal of light chains that is effective and can be maintained over time. Long haemodialysis sessions with HCO filters are a reasonable option, although new studies involving new chemotherapy agents and new direct extraction methods of light chains are needed.</p><p class="elsevierStylePara">The authors declare potential conflicts of interest:</p><p class="elsevierStylePara">The author(s) are paid for conferences.</p><p class="elsevierStylePara">The author(s) receive a travel bursary/allowance.</p><p class="elsevierStylePara"><a href="grande/11094_16025_26255_en_t111094.jpg" class="elsevierStyleCrossRefs"><img src="11094_16025_26255_en_t111094.jpg" alt="Characteristics of the six patients diagnosed with multiple myeloma"></img></a></p><p class="elsevierStylePara">Table 1. Characteristics of the six patients diagnosed with multiple myeloma</p><p class="elsevierStylePara"><a href="grande/11094_16025_26256_en_t211094.jpg" class="elsevierStyleCrossRefs"><img src="11094_16025_26256_en_t211094.jpg" alt="Days to diagnosis and to treatment with HCO, chemotherapy used in the six patients diagnosed with multiple myeloma"></img></a></p><p class="elsevierStylePara">Table 2. Days to diagnosis and to treatment with HCO, chemotherapy used in the six patients diagnosed with multiple myeloma</p><p class="elsevierStylePara"><a href="grande/11094_16025_26257_en_t311094.jpg" class="elsevierStyleCrossRefs"><img src="11094_16025_26257_en_t311094.jpg" alt="Complications in HCO haemodialysis "></img></a></p><p class="elsevierStylePara">Table 3. Complications in HCO haemodialysis </p><p class="elsevierStylePara"><a href="grande/11094_16025_26258_en_t411094.jpg" class="elsevierStyleCrossRefs"><img src="11094_16025_26258_en_t411094.jpg" alt="Maximum, minimum, mean, and standard deviation of phosphorous, calcium, magnesium, albumin, and creatinine values before haemodialysis sessions"></img></a></p><p class="elsevierStylePara">Table 4. Maximum, minimum, mean, and standard deviation of phosphorous, calcium, magnesium, albumin, and creatinine values before haemodialysis sessions</p><p class="elsevierStylePara"><a href="grande/11094_16025_26260_en_f111094.jpg" class="elsevierStyleCrossRefs"><img src="11094_16025_26260_en_f111094.jpg" alt="Percentage reduction in free light chain levels in the six patients treated with HCO haemodialysis at the end of treatment"></img></a></p><p class="elsevierStylePara">Figure 1. Percentage reduction in free light chain levels in the six patients treated with HCO haemodialysis at the end of treatment</p><p class="elsevierStylePara"><a href="grande/11094_16025_26262_en_f211094.jpg" class="elsevierStyleCrossRefs"><img src="11094_16025_26262_en_f211094.jpg" alt="Serum free light chain levels before and after haemodialysis in the six patients"></img></a></p><p class="elsevierStylePara">Figure 2. Serum free light chain levels before and after haemodialysis in the six patients</p><p class="elsevierStylePara"><a href="grande/11094_16025_26263_en_f311094.jpg" class="elsevierStyleCrossRefs"><img src="11094_16025_26263_en_f311094.jpg" alt="Percentage reduction in serum free light chains in the haemodialysis sessions of all six patients"></img></a></p><p class="elsevierStylePara">Figure 3. Percentage reduction in serum free light chains in the haemodialysis sessions of all six patients</p>" "pdfFichero" => "P1-E532-S3377-A11094-EN.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:4 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec439051" "palabras" => array:1 [ 0 => "Filtros de alto poro" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec439053" "palabras" => array:1 [ 0 => "Fracaso renal agudo" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec439055" "palabras" => array:1 [ 0 => "Mieloma múltiple" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec439057" "palabras" => array:1 [ 0 => "Hemodiálisis" ] ] ] "en" => array:4 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec439052" "palabras" => array:1 [ 0 => "High cut-off dialysers" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec439054" "palabras" => array:1 [ 0 => "Acute renal failure" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec439056" "palabras" => array:1 [ 0 => "Multiple myeloma" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec439058" "palabras" => array:1 [ 0 => "Haemodialysis" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Introducción:</span> El fracaso renal agudo (FRA) en el mieloma múltiple (MM) se presenta entre el 12-20% de los casos y la supervivencia de estos pacientes depende de la recuperación de la función renal. El 75% de los pacientes dependientes de diálisis no recuperan la función renal y su supervivencia media en situación de tratamiento sustitutivo es inferior al año. La nefropatía por cilindros es la causa más frecuente de fracaso renal y acontece en más del 55% de los casos, y en el 75% de aquellos que requieren diálisis. Para facilitar la recuperación de la función renal es imprescindible la disminución rápida de los niveles en sangre de cadenas ligeras. Una medida coadyuvante al tratamiento específico de la enfermedad ha sido la reducción de estas cadenas ligeras con plasmaféresis, sin que se haya demostrado claramente su eficacia, por lo que se ha propuesto el uso de hemodiálisis largas con filtros de alto poro (HCO), consiguiendo una tasa de recuperación superior al 60%. Presentamos la evolución en seis casos de pacientes con mieloma y fracaso renal agudo que fueron tratados con dichos filtros HCO, las complicaciones con este tipo de hemodiálisis y revisamos los pros y los contras de esta técnica. <span class="elsevierStyleBold">Metodología:</span> Seis pacientes diagnosticados de MM y FRA con necesidad de diálisis y niveles circulantes de cadena ligera por encima de 500 mg/l fueron tratados con hemodiálisis de 8 horas con filtro HCO. Al comienzo y al final de cada sesión se medían las cadenas ligeras séricas por nefelometría, así como otros parámetros. Al mismo tiempo los pacientes fueron tratados con quimioterapia según protocolos. <span class="elsevierStyleBold">Resultados: </span>A<span class="elsevierStyleBold"> </span>tres hombres y tres mujeres diagnosticados de MM y FRA, con inicio de los síntomas muy variable, desde 7 días a más de un año, se les realizó 90 sesiones de hemodiálisis largas con filtros HCO con un rango de entre 6 y 40 sesiones. El porcentaje de reducción de las cadenas ligeras desde el inicio del tratamiento hasta su finalización fue el 65% de media, excepto en un paciente, que fue del 12,6%. La media del porcentaje de reducción de la cadena ligera por sesión fue de 54,98 ± 17,27%. En el 28% de las sesiones se registró alguna complicación. El 48% de las complicaciones se debieron a la coagulación del sistema. No hubo grandes cambios en los niveles de albúmina prediálisis, calcio, fósforo y magnesio, aunque en algún caso se registraron valores disminuidos que no comportaron relevancia clínica. En tres pacientes la función renal se recuperó y permanecen vivos e independientes de la diálisis. En los casos biopsiados y que recuperaron función renal, la nefropatía por cilindros fue pura. Los pacientes que tardaron más en ser diagnosticados fueron los pacientes que no recuperaron función renal, y cuando se les efectuó biopsia el diagnóstico fue de nefropatía por cilindros más enfermedad por depósitos. <span class="elsevierStyleBold">Conclusión:</span> En nuestra experiencia, la hemodiálisis larga con filtros HCO es una alternativa razonable en el FRA causado por nefropatía por cilindros, alcanzando en nuestros casos una tasa de recuperación del 50%. En la recuperación influyeron: el tiempo transcurrido desde el inicio de los síntomas al diagnóstico de mieloma, los hallazgos histológicos, la rapidez de instauración del tratamiento quimioterápico y su respuesta y la eficacia en la extracción de cadenas ligeras. En cualquier caso, son necesarios nuevos estudios con nuevos agentes quimioterápicos y las nuevas técnicas de extracción directa de cadenas ligeras.</p>" ] "en" => array:1 [ "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Introduction: </span>Acute renal failure (ARF) occurs in 12%-20% of all multiple myeloma (MM) cases, and the survival of these patients depends on renal function recovery. Renal function is not recovered in 75% of dialysis-dependent patients, and their mean survival with replacement therapy is less than one year. Renal tubular disease is the most frequent cause of renal failure. It is present in more than 55% of renal failure cases and in 75% of those requiring dialysis. Rapid reduction of free light chain levels in the blood is necessary in order to recover renal function. One coadjuvant measure in treating the disease is reducing light chain levels with plasmapheresis, but its efficacy has not yet been clearly proven. Our proposal was therefore to use extended haemodialysis sessions with high cut-off dialysers (HCO-HD), obtaining a recovery rate of more than 60%. We present the progress of 6 patients with myeloma and acute renal failure who were treated with HCO-HD and the complications associated with using this type of haemodialysis. Then, we review the pros and cons of this technique. <span class="elsevierStyleBold">Method: </span>Six patients diagnosed with MM and ARF requiring dialysis and with serum free light chain levels above 500mg/l were treated with 8-hour haemodialysis sessions with an HCO-HD filter. Before and after each session, serum free light chain levels were measured by nephelometry; other parameters were recorded as well. At the same time, patients underwent chemotherapy according to protocols. <span class="elsevierStyleBold">Results: </span>The symptom onset times of the 3 men and 3 women diagnosed with MM and ARF were highly variable, from 7 days to more than 1 year. We performed 90 extended sessions with HCO-HD filters, and each patient underwent between 6 and 40 sessions. Free light chain levels decreased by a mean of 65% between treatment onset and completion, except in one patient who experienced a 12.6% reduction. The mean percentage of reduction of light chain levels per session was 54.98%±17.27%. A complication occurred during 28% of the sessions. Of these complications, 48% were due to system coagulation. There were no major changes in pre-dialysis albumin, calcium, phosphorous or magnesium levels, although lower values that were not clinically relevant were recorded in one case. Renal function was recovered in 3 patients, they are alive and dialysis-free. In biopsied cases that recovered renal function, the specimen showed tubular nephropathy only. Those patients who took longer to be diagnosed did not recover their renal function, and when biopsied, they were diagnosed with renal tubular disease and light chain deposition disease. <span class="elsevierStyleBold">Conclusion: </span>We found extended haemodialysis with HCO-HD filters to be a reasonable alternative in ARF caused by renal tubular disease, and achieved a recovery rate of 50% in our cases. Function recovery was influenced by the elapsed time between symptom onset and myeloma diagnosis, histological findings, promptness of starting chemotherapy, response to chemotherapy, and effectiveness of light chain extraction. In any case, further studies are needed to examine new chemotherapy agents and new direct free light chain removal techniques. </p>" ] ] "multimedia" => array:7 [ 0 => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11094_16025_26255_en_t111094.jpg" "Alto" => 678 "Ancho" => 2178 "Tamanyo" => 470403 ] ] "descripcion" => array:1 [ "en" => "Characteristics of the six patients diagnosed with multiple myeloma" ] ] 1 => array:8 [ "identificador" => "fig2" "etiqueta" => "Tab. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11094_16025_26256_en_t211094.jpg" "Alto" => 689 "Ancho" => 2161 "Tamanyo" => 421167 ] ] "descripcion" => array:1 [ "en" => "Days to diagnosis and to treatment with HCO, chemotherapy used in the six patients diagnosed with multiple myeloma" ] ] 2 => array:8 [ "identificador" => "fig3" "etiqueta" => "Tab. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11094_16025_26257_en_t311094.jpg" "Alto" => 522 "Ancho" => 1061 "Tamanyo" => 163411 ] ] "descripcion" => array:1 [ "en" => "Complications in HCO haemodialysis" ] ] 3 => array:8 [ "identificador" => "fig4" "etiqueta" => "Tab. 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11094_16025_26258_en_t411094.jpg" "Alto" => 516 "Ancho" => 2178 "Tamanyo" => 549002 ] ] "descripcion" => array:1 [ "en" => "Maximum, minimum, mean, and standard deviation of phosphorous, calcium, magnesium, albumin, and creatinine values before haemodialysis sessions" ] ] 4 => array:8 [ "identificador" => "fig5" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11094_16025_26260_en_f111094.jpg" "Alto" => 511 "Ancho" => 1011 "Tamanyo" => 184082 ] ] "descripcion" => array:1 [ "en" => "Percentage reduction in free light chain levels in the six patients treated with HCO haemodialysis at the end of treatment" ] ] 5 => array:8 [ "identificador" => "fig6" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11094_16025_26262_en_f211094.jpg" "Alto" => 1711 "Ancho" => 2100 "Tamanyo" => 835360 ] ] "descripcion" => array:1 [ "en" => "Serum free light chain levels before and after haemodialysis in the six patients" ] ] 6 => array:8 [ "identificador" => "fig7" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11094_16025_26263_en_f311094.jpg" "Alto" => 2000 "Ancho" => 1967 "Tamanyo" => 767106 ] ] "descripcion" => array:1 [ "en" => "Percentage reduction in serum free light chains in the haemodialysis sessions of all six patients" ] ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:28 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12528874" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on prognosis. Eur J Haematol 2000;65:175-81. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11007053" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Blade J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998;158:1889-93. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9759684" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Winearls CG.\u{A0}Acute myeloma kidney. Kidney Int 1995;48:1347-61. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8569099" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Magee C, Vella JP, Tormey W,\u{A0}Walshe JJ. Multiple myeloma and renal failure: One center's experience. Ren Fail 1998;20:597-606. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9713878" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Innes A, Cuthbert RJ, Russell NH, Morgan AG, Burden RP. Intensive treatment of renal failure in patients with myeloma. Clin Lab Haematol 1994;16:149-56. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7955923" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 1998;13:1438-45. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9641173" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Martín Reyes G, Valera A,\u{A0} Frutos\u{A0} MA, Ramos B, Ordóñez V, López de Novales E. Survival of myeloma patients treated with dialysis. Nefrologia 2003;23(2):131-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12778877" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "9.\u{A0}Sanders PW. Renal involvement in plasma cell dyscrasias. Curr\u{A0}Opin Nephrol\u{A0}Hypertens 1993;2(2):246-52. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7922184" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Ivany. B. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med 1990;114:986-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2117910" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bouvet JP, Frot JC, Ducaylar A, Benlarhache C, Muller F. [Gammopathies with oligoclonal electrophoretic patterns. Incidence, immunochemical nature and association with neoplastic pathology]. Presse Med 1983;12:2511-4." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sanders PW, Herrera GA, Chen A,\u{A0}Booker BB, Galla JH. Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J Clin Invest 1988;82:2086-96. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3198767" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Leboulleux M, Lelongt B, Mougenot B, Touchard G, Makdassi R, Rocca A,\u{A0}et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int 1995;48:72-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7564094" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Basnayake K, Stringer SJ,\u{A0}Hutchison CA, Cockwell P. The biology of immunoglobulin free light chains and kidney injury.\u{A0}Kidney International 2011;79:1289-301.\u{A0} <a href="http://www.ncbi.nlm.nih.gov/pubmed/21490587" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008;73:1282-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18385667" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Dimopoulos MA, Richardson PG, Schlag R. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009;27(36):6086-93. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19858394" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005;143:777. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16330788" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hutchison CA, Bradwell A, Cook M, Basnayake K, Basu S, Harding S, et al. Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis. Clin J Am Soc Nephrol 2009;4(4):745-54. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19339414" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Morgera S, Haase M, Kuss T, Vargas-Hein O, Zuckermann-Becker H, Melzar C, et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006;34(8):2099-104. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16763508" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: In-vitro and in-vivo studies. J Am Soc Nephrol 2007;18:886-95. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17229909" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive automated immunoassay for immunoglobulin FLCs in serum and urine. Clin Chem 2001;47:673-80. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11274017" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.\u{A0}J Am Soc Nephrol 2011;22:1129-36. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21511832" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988;33:1175. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3043077" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and\u{A0} chemotherapy. Arch Intern Med 1990;150:863-9." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs 2008;32(12):910-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19133018" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman Wh, Appel GB, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001;12:1482-92. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11423577" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A, et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomized controlled trial. Trials 2008;9:55. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18822172" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Grima DT, Hutchison CA. Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney. Curr Med Res Opin 2011;27(2):383-91. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21175375" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003200000001/v0_201502091620/X2013251412000570/v0_201502091620/en/main.assets" "Apartado" => array:4 [ "identificador" => "35441" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Originals" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003200000001/v0_201502091620/X2013251412000570/v0_201502091620/en/P1-E532-S3377-A11094-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000570?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 12 | 7 | 19 |
| 2024 October | 42 | 68 | 110 |
| 2024 September | 39 | 88 | 127 |
| 2024 August | 61 | 90 | 151 |
| 2024 July | 48 | 45 | 93 |
| 2024 June | 72 | 46 | 118 |
| 2024 May | 74 | 45 | 119 |
| 2024 April | 63 | 50 | 113 |
| 2024 March | 56 | 31 | 87 |
| 2024 February | 72 | 38 | 110 |
| 2024 January | 26 | 29 | 55 |
| 2023 December | 35 | 31 | 66 |
| 2023 November | 40 | 34 | 74 |
| 2023 October | 66 | 41 | 107 |
| 2023 September | 294 | 33 | 327 |
| 2023 August | 231 | 25 | 256 |
| 2023 July | 63 | 40 | 103 |
| 2023 June | 148 | 38 | 186 |
| 2023 May | 67 | 38 | 105 |
| 2023 April | 52 | 31 | 83 |
| 2023 March | 80 | 22 | 102 |
| 2023 February | 47 | 18 | 65 |
| 2023 January | 46 | 25 | 71 |
| 2022 December | 54 | 36 | 90 |
| 2022 November | 72 | 36 | 108 |
| 2022 October | 76 | 64 | 140 |
| 2022 September | 49 | 41 | 90 |
| 2022 August | 56 | 49 | 105 |
| 2022 July | 48 | 57 | 105 |
| 2022 June | 41 | 41 | 82 |
| 2022 May | 26 | 35 | 61 |
| 2022 April | 46 | 52 | 98 |
| 2022 March | 64 | 63 | 127 |
| 2022 February | 52 | 75 | 127 |
| 2022 January | 55 | 30 | 85 |
| 2021 December | 78 | 36 | 114 |
| 2021 November | 55 | 43 | 98 |
| 2021 October | 78 | 42 | 120 |
| 2021 September | 44 | 39 | 83 |
| 2021 August | 62 | 42 | 104 |
| 2021 July | 59 | 37 | 96 |
| 2021 June | 222 | 35 | 257 |
| 2021 May | 294 | 37 | 331 |
| 2021 April | 1590 | 128 | 1718 |
| 2021 March | 78 | 44 | 122 |
| 2021 February | 91 | 21 | 112 |
| 2021 January | 46 | 15 | 61 |
| 2020 December | 46 | 18 | 64 |
| 2020 November | 51 | 14 | 65 |
| 2020 October | 33 | 14 | 47 |
| 2020 September | 86 | 5 | 91 |
| 2020 August | 47 | 13 | 60 |
| 2020 July | 86 | 11 | 97 |
| 2020 June | 58 | 16 | 74 |
| 2020 May | 74 | 17 | 91 |
| 2020 April | 67 | 13 | 80 |
| 2020 March | 58 | 21 | 79 |
| 2020 February | 85 | 31 | 116 |
| 2020 January | 99 | 30 | 129 |
| 2019 December | 85 | 24 | 109 |
| 2019 November | 114 | 35 | 149 |
| 2019 October | 75 | 21 | 96 |
| 2019 September | 99 | 29 | 128 |
| 2019 August | 58 | 15 | 73 |
| 2019 July | 46 | 28 | 74 |
| 2019 June | 74 | 25 | 99 |
| 2019 May | 78 | 27 | 105 |
| 2019 April | 108 | 40 | 148 |
| 2019 March | 62 | 29 | 91 |
| 2019 February | 40 | 9 | 49 |
| 2019 January | 43 | 24 | 67 |
| 2018 December | 103 | 46 | 149 |
| 2018 November | 145 | 17 | 162 |
| 2018 October | 124 | 11 | 135 |
| 2018 September | 117 | 21 | 138 |
| 2018 August | 98 | 25 | 123 |
| 2018 July | 72 | 18 | 90 |
| 2018 June | 77 | 15 | 92 |
| 2018 May | 89 | 18 | 107 |
| 2018 April | 89 | 8 | 97 |
| 2018 March | 81 | 12 | 93 |
| 2018 February | 71 | 10 | 81 |
| 2018 January | 75 | 8 | 83 |
| 2017 December | 81 | 12 | 93 |
| 2017 November | 79 | 20 | 99 |
| 2017 October | 84 | 6 | 90 |
| 2017 September | 73 | 14 | 87 |
| 2017 August | 66 | 16 | 82 |
| 2017 July | 75 | 16 | 91 |
| 2017 June | 70 | 6 | 76 |
| 2017 May | 107 | 11 | 118 |
| 2017 April | 86 | 14 | 100 |
| 2017 March | 70 | 21 | 91 |
| 2017 February | 155 | 7 | 162 |
| 2017 January | 56 | 10 | 66 |
| 2016 December | 107 | 11 | 118 |
| 2016 November | 164 | 17 | 181 |
| 2016 October | 237 | 14 | 251 |
| 2016 September | 355 | 17 | 372 |
| 2016 August | 310 | 14 | 324 |
| 2016 July | 294 | 22 | 316 |
| 2016 June | 215 | 0 | 215 |
| 2016 May | 204 | 0 | 204 |
| 2016 April | 146 | 0 | 146 |
| 2016 March | 167 | 0 | 167 |
| 2016 February | 143 | 0 | 143 |
| 2016 January | 147 | 0 | 147 |
| 2015 December | 174 | 0 | 174 |
| 2015 November | 129 | 0 | 129 |
| 2015 October | 134 | 0 | 134 |
| 2015 September | 139 | 0 | 139 |
| 2015 August | 109 | 0 | 109 |
| 2015 July | 86 | 0 | 86 |
| 2015 June | 53 | 0 | 53 |
| 2015 May | 78 | 0 | 78 |
| 2015 April | 7 | 0 | 7 |
Show all
